Stuart Lutzker
Vermögen: 5 Mio $ am 30.06.2026
Vermögen: 5 Mio $ am 30.06.2026
Stuart Lutzker is the founder of Arrivent BioPharma, Inc., founded in 2021, holding the titles of Director and President-Research & Development since 2022.
Former job includes VP, Head-Oncology & Early Clinical Development at Genentech, Inc. from 2004 to 2021.
Education includes undergraduate studies at The Trustees of Columbia University in The City of New York and a doctorate from Columbia University College of Physicians & Surgeons.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
ARRIVENT BIOPHARMA, INC. 0,32 % | 21.04.2026 | 147.744 ( 0,32 % ) | 5 Mio $ | 30.06.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| ARRIVENT BIOPHARMA, INC. | Gründer | 14.04.2021 |
| Unternehmen | Position | Ende |
|---|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Corporate Officer/Principal | 01.03.2021 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 4 |
|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Health Technology |
The Trustees of Columbia University in The City of New York
The Trustees of Columbia University in The City of New York Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Columbia University College of Physicians & Surgeons
Columbia University College of Physicians & Surgeons Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Arrivent BioPharma, Inc.
Arrivent BioPharma, Inc. Pharmaceuticals: OtherHealth Technology Engages in development and commercialization of cancer medicines | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen